Overview

Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa

Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral vadadustat for the treatment of anemia in hemodialysis participants converting from epoetin alfa therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Akebia Therapeutics
Treatments:
Epoetin Alfa
Glycine